Entrada Therapeutics (TRDA) COO sells 15,010 shares in planned 10b5-1 trades

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Entrada Therapeutics President & COO Nathan J. Dowden reported open-market sales of a total of 15,010 shares of common stock. He sold 3,116 shares on March 9, 2026 at a weighted average price of $13.024 per share and 11,894 shares on March 10, 2026 at a weighted average price of $13.0476 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. After the most recent sale, Dowden directly holds 198,588 shares of Entrada Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 15,010 shares ($195,771)

Net Sell 2 txns

Insider Dowden Nathan J

Role President & COO

Sold 15,010 shs ($196K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,894	$13.0476	$155K
Sale	Common Stock	3,116	$13.024	$41K

Holdings After Transaction: Common Stock — 198,588 shares (Direct)

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

03/11/2026 - 04:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dowden Nathan J

(Last)

(First)

(Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & COO

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/09/2026		S⁽¹⁾		3,116	D	$13.024⁽²⁾	210,482	D
Common Stock	03/10/2026		S⁽¹⁾		11,894	D	$13.0476⁽³⁾	198,588	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Entrada Therapeutics (TRDA) report for Nathan J. Dowden?

Entrada Therapeutics reported that President & COO Nathan J. Dowden sold a total of 15,010 shares of common stock in two open-market transactions. These sales occurred on March 9 and March 10, 2026, as disclosed in a Form 4 insider filing.

At what prices did Nathan J. Dowden sell TRDA shares in the latest Form 4?

Nathan J. Dowden sold TRDA common stock at weighted average prices of $13.024 and $13.0476 per share. Footnotes explain these were multiple trades within ranges of $13.00–$13.20 and $13.00–$13.09, with full price breakdowns available on request.

How many Entrada Therapeutics (TRDA) shares does Nathan J. Dowden hold after these sales?

Following the reported open-market sales, Nathan J. Dowden directly holds 198,588 shares of Entrada Therapeutics common stock. This post-transaction holding reflects his remaining direct equity position after selling a combined 15,010 shares in March 2026.

Were Nathan J. Dowden’s TRDA stock sales made under a Rule 10b5-1 trading plan?

Yes. The Form 4 footnotes state that the reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Nathan J. Dowden on March 7, 2025. Such plans pre-schedule trades to help manage insider transactions.

What type of transactions did the TRDA Form 4 disclose for Nathan J. Dowden?

The Form 4 discloses open-market sales of Entrada Therapeutics common stock by Nathan J. Dowden. Both transactions are coded “S” for sale and described as sales in open market or private transactions, with no derivative exercises reported.

How many TRDA shares did Nathan J. Dowden sell in each transaction reported?

Nathan J. Dowden sold 3,116 shares of Entrada Therapeutics common stock on March 9, 2026 and 11,894 shares on March 10, 2026. Together, these sales total 15,010 shares as reported in the transaction summary of the Form 4.